ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from Â鶹ӳ» MD Anderson Cancer Center.
Results from the Phase II single arm multicenter trial, presented today at the 2025 American Society of Clinical...
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...